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miR-222 in the control group enhancing the performance of these two elements
as possible negative regulators of the Hb F levels. miR-449th, miR-449b and
miR-4795 were highly expressed in the control group.The miR-34c-5p, was
more expressed in the group with sickle cell disease and was correlated with
miR-26b (ρ=0.7). The miR-221 and miR-222 were correlated with each other
(ρ=0.7) and miR-151-3p (ρ=ρ=0.72 and 0.98, respectively). Furthermore, miR-
96 showed more correlations in the group with sickle cell anemia.
Summary and Conclusions: Our results shown the presence of differentially
expressed miRNAs predicted the regulation of gamma-globin genes among
Hb AA individuals with low levels of Hb F and individuals with sickle cell anemia
with increased Hb F induced by treatment with HU. Some of these elements
have validated and compared with the erythropoiesis regulation of gamma-
globin genes, whereas other miRNAs have not yet been associated with these
procedures.
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POSSIBLE INTERPLAY OF MICRORNA AND TRANSCRIPTION FACTORS
DURING IN VITRO ERYTHROID CULTURE OF CD34+ CELLS IN SICKLE
CELL ANEMIA
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Background: The clinical severity of the sickle cell anemia (SCA) can be affect-
ed by a number of modifying factors including HbF levels and the coinheritance
of alpha-thalassemia. Furthermore, key regulators such as microRNAs (miRs)
and transcription factors (TFs) are involved in the regulatory mechanism of
HbF production, however this regulatory mechanism is unclear.
Aims: To investigate miRs and TFs expression during in vitro erythroid differ-
entiation in normal and SCA erythropoiesis.
Methods: Peripheral blood CD34+ cells were isolated from 4 patients who pre-
sented homozygous HbS genotype (HBSS) and from 4 healthy subjects (CON).
The cells were cultured in a liquid system stimulating erythropoiesis and col-
lected on days 7, 10, and 13 to analyze miRs and the TFs expression profile.
In silico prediction was performed by TargetScanHuman software v 6.2 to verify
possible interactions between miRs and TFs.
Results: Quantitative PCR showed that two miRs were down-regulated during
HBSS erythropoiesis: miR-223 on days 7 and 10, and miR 486-3p on day 10
(P<0.05). Seven miRs were up-regulated: 146a-5p, 221 and 222 on day 10,
and 15a, 144-3p, 150-5p and 155-5p on day 13 (P<0.05). NFE2, SP1, ETO2
and FOXO3 were decreased on day 13 (P<0.05), while LMO2 and LDB1 were
up-regulated on days 10 and 13, respectively (P<0.05). Increased levels of
TAL1 were observed on days 10 and 13 (P<0.05). GATA1 expression did not
change significantly. In silico analysis predicted miR interactions for the 3’
untranslated region of TFs : 146a-5p–NFE2, miR-155-5p– SP1, miR-221–
FOXO3, miR-222 – FOXO3, miR-486-3p–LDB1, and miR-486-3p–TAL1. Stud-
ies have shown that mice lacking the transcription factor NF-E2 present
hemolytic anemia, while the downregulation of ETO2 and SP1 contributes to
the activation of TFs involved in the GATA1-complex, such as LDB1, TAL1 and
LMO2. Based on our preliminary results, the upregulation of these TFs may be
associated with the decreased expression of ETO2 and SPI1 in HBSS cultures.
We also suggest that the miRs-targets 155, 15a, 486-3p and 146a-5p may be
contributing to changes in the expression of these TFs. Studies demonstrated
that miRs 15a and 150-5p regulate the TF cMYB and its downregulation leads
to an increase in HbF levels. Our results of low levels of cMYB with concomitant
increases in these miRs in HBSS cultures are in agreement with the previous
studies. An association of high miR-144-3p expression with a severe anemia
phenotype in SCA, oxidative damage and hemolysis of HBSS erythrocytes
cells has been previously described. Additionally, up-regulation of FOXO3 cor-
related to an antioxidant gene expression response, which protects erythroid
cells from cellular stress. We also found the high levels of miR-144-3p in HBSS
cultures and also showed a downregulation of FOXO3, which may be associ-
ated with upregulation of its miRs-target 221/222. 
Summary and Conclusions: Our data show relevant associations between
miRNAs and their possible targets during in vitro erythroid differentiation. These
results suggest that miRNAs represent a class of molecules that may contribute
to hematopoietic process and may have a role in physiopathology of SCA.
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CATEGORIZATION OF CLINICAL SEVERITY IN PYRUVATE KINASE
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Background: PKD is the most common glycolytic defect causing congenital
non-spherocytic hemolytic anemia. An international, multicenter Natural History
Study (NHS) has been established to collect retrospective and prospective
clinical data on PKD patients (pts).
Aims: To categorize PKD clinical severity based on degree of anemia, trans-
fusion history, and splenectomy status and to identify predictors and prevalence
of complications in the severity groups.
Methods: 105 pts with PKD enrolled on the PKD NHS at 14 IRB approved sites
from March 2014 to January 2015. Pts were randomly assigned to either the
test set (n=75) or future validation set. For this analysis, baseline and retro-
spective enrollment data were included from the 75 test set pts. PKD pts were
categorized into 4 distinct severity groups (Gp1-Gp4), with increasing severity
of the disease: Gp1. Never regularly transfused +/-prior acute transfusions; Gp2.
Regular transfusions prior to splenectomy (SPL), post-SPL baseline hemoglobin
(hb) >8.7 g/dl; Gp3. Regular transfusions prior to SPL, post-SPL baseline hb
≤8.7 g/dl; and Gp4. Splenectomized and currently regularly transfused. Gp2
and 3 were regularly transfused prior to SPL and transfusion independent after
SPL and are distinguishable by post-SPL baseline hb. The median hb (8.7 g/dl)
from Gp2 and 3 was used to discriminate between pts who were less anemic
versus more anemic. Ordinal logistic regression models were used to test for
association between clinical characteristics and severity group.
Results: The Table shows the characteristics of Gp1-4. In Gp1, only 42% of pts
were splenectomized. Younger age at diagnosis (p=0.04) was significantly asso-
ciated with increased severity of disease. There were no significant differences
in groups based on gender, ethnicity, or race. There was a significant trend for
increasing ferritin (p=0.03) and liver iron concentration (LIC, p=0.04) with
increasing PKD clinical severity, and more severe groups were more likely to
have received chelation therapy (p<0.01). Some Gp1 pts developed iron over-
load despite the absence of a history of regular transfusions. There was also a
trend for higher rates of cholecystectomy (p=0.01) with increasing clinical sever-
ity. For certain complications, there was no evidence to support an association
with clinical severity, including aplastic crises (overall rate 16%), extramedullary
hematopoiesis (12%), and pregnancy complications of the affected mother
(55%), as well as the requirement for exchange transfusion in the newborn peri-
od (44%). The reticulocyte count was incrementally higher with increasing clinical
severity in the non-regularly transfused groups from Gp1 to Gp3 (p=0.02), even
after controlling for splenectomy status. As expected, multiple genotypes were
found in this cohort. Pts with the common, Amish, homozygous 1436G>A muta-
tion were found in Gp1, 2, and 3, which may indicate a contribution of other
genetic or environmental factors to clinical severity.
Tabella 1. Demographyc and Clinical Features of the Classification
Groups of Clinical Severity in PKD.
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